Key Takeaways

  • Tirzepatide cut adolescents' BMI by 18.5% over 72 weeks versus a 0.5% rise on placebo, in a 160-teen trial run at 31 sites including Canada.
  • 53.5% of teens on the drug dropped below the obesity threshold, versus 7.1% on placebo.
  • 81.5% had gastrointestinal side effects, the trial was funded by Eli Lilly, and the drug is not approved for adolescents.

What happens when one of the strongest weight-loss drugs meets teenagers?

Tirzepatide — sold as Zepbound and Mounjaro — is one of the most powerful obesity drugs ever approved for adults. Its first major test in adolescents is now out, and the results are striking.

The SURMOUNT-ADOLESCENTS trial, published November 15 in JAMA, enrolled 160 teens aged 12 to 17 at 31 hospitals and research centres, including sites in Canada. For 72 weeks, they received weekly tirzepatide injections or a placebo, alongside lifestyle support.

BMI in the tirzepatide group fell 18.5% over the trial. In the placebo group, it rose 0.5%.

More than half the teens on the drug — 53.5% — dropped below the obesity threshold entirely, compared with 7.1% on placebo. Nearly half achieved a BMI reduction of 20% or more.

And their growth was not slowed: height and puberty progressed normally in both groups.

The catch? An unhappy stomach — and more

The trade-off was the familiar GLP-1 one, amplified.

81.5% of teens on tirzepatide had gastrointestinal side effects — nausea, vomiting and diarrhea — mostly mild to moderate and worst while the dose was being raised.

About 9% stopped the drug because of side effects, versus none on placebo, and roughly one in five used anti-nausea medication.

Serious side effects were uncommon but higher on the drug than on placebo: 7.4% versus 3.9%.

One detail readers should know: the trial was funded by Eli Lilly, tirzepatide's maker, which also helped design the study and prepare the manuscript. That is a standard arrangement in drug trials, but it is a real conflict of interest.

The study also cannot answer the longest questions: what years of treatment through adolescence do to a still-developing body, and what happens to weight when the injections stop.

What this means for families

Tirzepatide is not approved for adolescents, and this trial alone will not change that overnight.

But with teen obesity rising — and lifestyle programs alone rarely producing results like these — regulators in Canada and the U.S. now have hard data to weigh.

On one side: an 18.5% BMI reduction, with more than half of teens no longer meeting the definition of obesity.

On the other: an 81.5% chance of stomach trouble, a 9% dropout rate, and unknowns that will take years to resolve.

Health note: Tirzepatide is a prescription drug approved for adults; it is not approved for weight loss in adolescents. The teens in this trial were closely monitored by specialists. Families should discuss any weight concerns with their doctor rather than seeking GLP-1 drugs through online sellers.

The Twikup Take

An 18.5% BMI cut in teenagers is the kind of result that changes what doctors can honestly offer families who have tried everything else. The side-effect burden is real, the long-term unknowns are real too — but the era of GLP-1 drugs for adolescents is clearly coming, and Canada helped produce the evidence.

Image: Illustrative image.

Sources